Brief: Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due To Futility
20/04/2026 13:02
April 20 (Reuters) - Gilead Sciences Inc GILD.O: ARCUS BIOSCIENCES INC - DISCONTINUES PHASE 3 STAR-121 STUDY WITH GILEAD DUE TO FUTILITY - SEC FILING ARCUS BIOSCIENCES INC - STAR-121 AND PHASE 2 EDGE-LUNG STUDIES TO BE DISCONTINUED - SEC FILING ARCUS BIOSCIENCES INC - GILEAD'S OPTION RIGHTS UNDER COLLABORATION AGREEMENT TO END JULY 14, 2026 - SEC FILING Source text: [ID:n0001724521-26-000021] Further company coverage: GILD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering